49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma
Abstract Background Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated efficacy in advanced clear-cell renal cell carcinoma (ccRCC) in patients previously received immunotherapy (IO) and anti-angiogenics. However, comorbidities pose a challenge in cancer management and often limit inclusion...